Schizophrenia Clinical Trial
Official title:
Study of Role of Anti-Inflammatory Agents in Patients With Schizophrenia
There is some evidence that anti-inflammatory treatment may have beneficial effects in
schizophrenia and major depression. Cox-2 inhibitors have been tested in preliminary clinical
trials for schizophrenia and depression, showing favourable effects compared to placebo
(Muller and Schwarz et al 2009).
Statins were introduced as cholesterol-lowering agents but have found much wider usage. They
are anti-inflammatory agents and thus similar to the Cox-2 inhibitors, which have shown some
ability as adjuncts to improve the symptoms of schizophrenia in preliminary studies. The
statins are also known to decrease C-reactive protein (CRP), which has been shown in an
SMRI-funded study to be elevated in a study of individuals with schizophrenia. Fan et al
(2007) demonstrated in a small study in patients with schizophrenia that higher than normal
levels of CRP (>0.50 mg/dl) was associated with marked negative symptoms and higher total
PANSS scores.
Ondansetron is a serotonin (5-HT3) receptor antagonist that is generic and widely used to
prevent nausea and vomiting in patients receiving chemotherapy for cancer. GSK did a small
study on it as an antipsychotic in the 1980s. Since then, several small studies have
suggested that it is effective as an adjunct drug in improving the symptoms of schizophrenia.
Statins are widely used in schizophrenia sufferers, particularly those taking second
generation antipsychotics, to treat hypercholesterolemia. Both drugs are well tolerated and
their side effect profiles well understood.
We propose to conduct a feasibility study in patients with chronic schizophrenia to explore
the adjunct use of simvastatin and ondansetron on positive, negative and general
psychopathology in comparisons to treatment as usual (TAU) over a 12 week period.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |